Back to library / Business & Productivity 商业与效率 • 2019-08-29 • About 3m 3s

The Economics of Sky-High Drug Prices: R&D Failure Rates and Market Dynamics

Astronomical drug prices stem from massive sunk R&D costs amortized across tiny patient populations; respecting market dynamics and profit incentives is the only sustainable path to spur innovation and ultimately drive prices down.

🌐 Translated by AI from the Chinese original View original (中文) · 2026-10-26

#Pharmacoeconomics #R&D Costs #Economies of Scale #Market Mechanics #Orphan Drugs
Anonymous · tap again to undo

The Economics of Sky-High Drug Prices: From R&D Failure Rates to Market-Driven Price Reductions

⚡ Core Insight

The core paradox behind sky-high drug prices lies not in raw materials or manufacturing, but in the immutable law of R&D: “creating is ten thousand times harder than copying.” Developing a novel drug takes over a decade, costs billions of dollars, and faces an abysmal ~4% success rate. What consumers ultimately pay for is the cost of subsidizing the 96% of projects that failed. For rare disease therapeutics with tiny patient populations, the lack of a massive user base to amortize these fixed costs inevitably results in staggering unit prices. Moral outrage and administrative price caps only stifle the incentive to innovate; only by offering viable profit incentives to attract capital and competitors can market dynamics ultimately lower prices for the public.

🗺️ Knowledge Map

mindmap
  root((First Principles of High Drug Prices))
    High R&D Costs
      Creation Harder than Replication
      Decade-Long R&D Cycles
      Only ~4% Clinical Success Rate
      Absorbing Sunk Costs from 96% Failures
    Lack of Economies of Scale
      Tiny and Fragmented Patient Base
      Cannot Amortize Fixed Costs Like Mass Goods
      High Per-Case Amortized Cost for Rare Diseases
    Market Mechanisms and Incentives
      Drugs are Essentially Commodities
      Moral Pressure Suppresses Supply Incentives
      Superprofits Attract Capital and Top Talent
      Full Competition Drives Supply and Price Drops

⏱️ Key Points & Timeline

  • [00:00 - 00:33] The Fundamental Difference Between Copying and Creating: Synthesizing a known chemical molecule or pirating software is trivial, but uncovering why that specific molecule works requires cognitive breakthroughs and trial-and-error costing billions of dollars.
  • [00:33 - 01:14] Low Success Rates and Sunk Cost Amortization: Moving from target screening through Phase III clinical trials takes over a decade with an average success rate of just 4%; high drug prices essentially amortize the total trial-and-error costs of all scrapped projects.
  • [01:14 - 01:39] The Decisive Impact of Economies of Scale on Unit Price: Mass consumer goods dilute fixed asset investments across billions of users, whereas rare disease populations are minuscule and geographically dispersed; lacking scale to amortize costs drives unit prices through the roof.
  • [01:39 - 02:21] Commodity Nature and the Crowding-Out Effect of Moralizing: Drugs are fundamentally commercial solutions. Excessive moral outcry will not lower prices; it merely drives innovators out of the market, leaving patients with no therapies at all.
  • [02:21 - 03:03] Profit-Driven Incentives as the Ultimate Engine for Price Drops: Only sufficient profit margins can hedge against prolonged, high-risk development cycles, draw top-tier talent and capital into the field, and spark the competitive pressure that drives prices down over the long term.

💡 First Principles & Mechanics

1. Decreasing Marginal Costs of Creation vs. Irreversible Sunk Fixed Costs

The physical manufacturing cost of a finished drug is often negligible (a few milliliters of solvent and packaging cost mere dollars), but the R&D invested in that very first dose can exceed a billion dollars. Drug development must navigate target identification, lead compound optimization, in vitro and animal models, Phase I-III clinical trials, and New Drug Applications (NDA). At any stage, failing a single endpoint wipes out the entire investment (as seen in repeated Phase III setbacks for HIV vaccines). Commercial pricing must not only recoup active production costs, but also absorb the losses of hundreds of failed predecessor projects.

2. Economies of Scale and the Rare Disease Pricing Dilemma

The unit price of an industrial product follows: Unit Fixed Cost + Unit Variable Cost. Products like smartphones and semiconductors rapidly amortize fixed infrastructure and R&D across hundreds of millions of consumers. Rare disease drugs, however, target small, globally fragmented patient cohorts. This tiny denominator keeps unit amortized costs astronomical—a structural constraint imposed by market mechanics, not corporate malice.

3. Market Dynamic Equilibrium and the Virtuous Innovation Loop

  • The Perils of Myopic Intervention: Forcibly capping prices or voiding patents provides short-term financial relief at the cost of destroying the risk-reward ratio for capital. Pharma companies respond by shuttering relevant pipelines, shutting future patients out of life-saving treatments permanently.
  • The Profit-Driven Flywheel: High return expectations → Willingness to fund long-cycle, high-risk R&D → Attraction of elite scientists and massive capital → Pipeline scaling → Entry of peer competitors and generics → Expanded supply and natural, market-driven price deflation.

🛠️ 24-Hour Action Checklist

  • Build a “Total Cost Accounting” Mental Model: When evaluating pricing for cutting-edge technologies (e.g., silicon chips, LLM compute infrastructure, patented therapeutics), explicitly factor sunk R&D costs and trial failure rates into the equation instead of falling into the “bill of materials” fallacy.
  • Trace an End-to-End Orphan Drug Pipeline: Select a benchmark drug (e.g., Nusinersen), research its initial filing year, clinical trial duration, cumulative R&D spend, and target patient population size to quantitatively model the mathematical logic behind its unit price.
  • Audit Amortization Mechanics in Your Own Ventures: Review the fixed R&D expenditure versus addressable user base of your current product or business. If targeting a niche market, prioritize high unit value and premium positioning rather than entering a destructive price war.
Loading video…
CDN stream ready
00:00 03:03

🎙️ Transcript & timeline

22 cues
00:00

帮我把牛肉的价格打下来,没问题,帮我把红酒的价格打下来,没问题,帮我把70万

00:08

的药价打下来。稍等,它凭什么能卖70万?几毫升的化学药品加上药瓶,复制不难,创造难。

00:16

创造难药物分子不难知道为什么是这个药物分子才难开发一个操作系统耗之几百个亿美

00:24

金都不一定能开发成功。代码拷入盗版碟极容易,创造远难于复制。开发一款新药平均研发投入

00:33

资本成本高达十亿美元,辛辛苦苦花钱花精力还不一定研发成功。选中靶点、先导化合物筛选再到临床

00:41

优化前的一药三期再到最终上市申请从最初的立项到推向市场十几年的时间只有百分之

00:49

4%的成功率,任何一个环节出问题,都会导致研发夭折。艾滋疫苗就是临床三期遭遇的难题

00:58

,至今十七年未能研发出来。而这些失败的费用是要平摊到每个新药身上的。我们支付

01:06

的很多药费实际是给这些失败的研发品买单的。就算是研发成功就算推向市场也还面临

01:14

一个问题量产一台光刻机几个亿一条产品线几十个亿而为什么一个手机只卖几千块因为

01:23

量产几十个亿的消费者平摊了研发费用固定成本但罕见的用户极为有限几分散在各个国

01:31

家,不同国家药批耽误量产,分摊下来必定单价高。指责药企黑心挣钱违背了市场铁律。药品虽是治病

01:39

救人的但本质一商品市场造成高价么降价必要依靠市场。如果鸡蛋不够吃,应该是鼓励

01:48

更多人去养鸡,而不是杀鸡取卵。如果药品不够便,该是鼓励更多药剂去挣钱不是指责

01:56

他们唯利是图。“药卖这么贵我吃三年房子都吃没了”,这句话的另一个版本是:倘若没有这些药,就不是

02:04

房子没了,是人没了药企不是让人生病的只是给生病的人提供解决方案的如果一个药因

02:13

提供方被口诛笔伐就会导致更多的药企不敢提供方案。那些因为缺乏药物而消失的生命

02:21

从来没有人留意,似乎他们从来不存在一样方案一定是有代价的。我们无法做的无损,

02:29

只能让代价逐渐降低科技一蹴而就市场一点时间而利润就是最好的推进起利润足够大,

02:38

才会有人肯花十几年的心血等待回报,无畏风险反复尝试。利润足够大才会有资金用于

02:46

医药研发理论研究规模效应降低成本。利润足够大才会吸引更多的顶尖人才少走弯路加

02:54

快速度,利润足够大才会引来足够的竞争对手,你争我夺,压低价格,尊重市场规律,才有正向反馈。药品当做商品才能真正降价。

💬 Comments

—

Loading comments…

    Log in to comment. Replies are one level deep, comments are public immediately, and the admin can remove any of them. Log in to comment →